Related Experiment Videos
Evaluation of lamoxactam in the treatment of severe bacterial infections
Abstract:
We investigated the clinical efficiency and safety of lamoxactam for treatment of 28 episodes of infection in 26 adult patients (15 males and 11 females) whose ages ranged from 17 to 83 years (mean 48.7). 4 patients had 'ultimately fatal diseases' and the remaining 22 had 'nonfatal diseases'. The clinical condition at the beginning of treatment was 'critical' or 'poor' in 15 cases. Episodes of infection treated were: 14 intraabdominal, 9 bacteremia, 5 nephro-urinary, 3 osteomyelitis, and a miscellaneous group including pneumonia, soft tissue, parameningeal focus and infected V-P shunt. A total of 34 microorganisms were responsible for 25 episodes of infection. 15 and 10 episodes were mono- and polymicrobial, respectively. Isolated microorganisms included 13 aerobic facultative gram-negative bacillus, 5 facultative gram-positive cocci, and 16 anaerobes. Total dosage of lamoxactam administered by patient ranged from 24 to 234 g (mean 57.6 g), and mean duration of therapy was 15.2 days (range 8-42 days). The overall rate of clinical response to lamoxactam was excellent, amounting to 84% of episodes and 91% of patients. Local and general tolerance was good, and lamoxactam had to be discontinued only once during therapy due to an episode of neutropenia. Enterococcal colonization (5 of 26 patients, 19%) and superinfections (3 of 26 cases, 11.5%) were undesirably frequent in our patients. Lamoxactam seems to be an effective and safe single-agent therapy for many bacterial infections. The possibility of enterococcal colonization and superinfections should be monitored, specially in patients with urinary or intraabdominal infections.
Insights
Lamoxactam demonstrated excellent clinical efficacy (84% of episodes) and safety in treating various bacterial infections in adults. Monitoring for enterococcal colonization and superinfections is recommended, particularly for intraabdominal and urinary cases.
Area of Science:
- Infectious Diseases
- Clinical Pharmacology
- Antimicrobial Therapy
Background:
- Bacterial infections pose significant clinical challenges, necessitating effective and safe therapeutic agents.
- Assessing novel antibiotic efficacy and safety profiles is crucial for optimizing patient care.
- Lamoxactam is an antibiotic agent whose clinical utility requires thorough investigation.
Purpose of the Study:
- To evaluate the clinical efficiency and safety of lamoxactam as a treatment for various bacterial infections in adult patients.
- To determine the overall response rate and identify potential adverse events associated with lamoxactam therapy.
- To assess the incidence of specific complications such as enterococcal colonization and superinfections.
Main Methods:
- Prospective investigation of 28 infection episodes in 26 adult patients treated with lamoxactam.
- Analysis of clinical response rates, including overall efficacy and patient outcomes.
- Monitoring of local and general tolerance, adverse events (e.g., neutropenia), and superinfections.
Main Results:
- Lamoxactam achieved an excellent overall clinical response rate of 84% for infection episodes and 91% for patients.
- The antibiotic exhibited good local and general tolerance, with only one discontinuation due to neutropenia.
- Enterococcal colonization (19%) and superinfections (11.5%) were observed, particularly in patients with intraabdominal or urinary tract infections.
Conclusions:
- Lamoxactam is a highly effective and safe single-agent therapy for a broad spectrum of bacterial infections.
- Clinicians should be vigilant for potential enterococcal colonization and superinfections, especially in susceptible patient groups.
- Further monitoring is warranted to manage these potential complications during lamoxactam treatment.